Our results generated by scRNA-seq analysis of PBMC in an initial discovery cohort of patients with melanoma indicated that S100A9 expression by monocytes in cluster 1 was one of the most differentially expressed genes between responders and non-responders to anti-PD1 therapy. This evidence concerns the gene S100A9 and melanoma.